MediciNova (TSE:4875) Cyclically Adjusted FCF per Share: 円-40.69 (As of Mar. 2026)


TSE:4875 MediciNova Inc TSE:4875
28 GF Score
Price 円227.00
! 2 Warning Signs
View Full Analysis

What is MediciNova Cyclically Adjusted FCF per Share?

MediciNova TSE:4875 -1.30% 28 Cyclically Adjusted FCF per Share is 円-40.69 as of Mar. 2026. GuruFocus rates TSE:4875 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

MediciNova's adjusted free cash flow per share for the three months ended in Mar. 2026 was 円-11.222. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is 円-40.69 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 2.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 17.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of MediciNova was 60.70% per year. The lowest was 2.50% per year. And the median was 21.65% per year.

As of today (2026-07-09), MediciNova's current stock price is 円227.00. MediciNova's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was 円-40.69. MediciNova's Cyclically Adjusted Price-to-FCF of today is .


MediciNova  (TSE:4875) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


MediciNova Cyclically Adjusted FCF per Share Related Terms


MediciNova Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for MediciNova's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediciNova Cyclically Adjusted FCF per Share Chart

MediciNova Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.61 -40.57 -32.20 -41.35 -41.22

MediciNova Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.67 -37.51 -36.02 -41.22 -40.69

TSE:4875 vs TCRX, PMVP, BSEM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, MediciNova's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediciNova Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediciNova's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where MediciNova's Cyclically Adjusted Price-to-FCF falls into.


TSE:4875
28GF Score
MediciNova Inc TSE:4875
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediciNova Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MediciNova's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-11.222/330.2130*330.2130
=-11.222

Current CPI (Mar. 2026) = 330.2130.

MediciNova Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -4.841 241.018 -6.633
201609 -4.774 241.428 -6.530
201612 -3.619 241.432 -4.950
201703 -8.330 243.801 -11.282
201706 -4.517 244.955 -6.089
201709 -6.047 246.819 -8.090
201712 -3.262 246.524 -4.369
201803 -11.084 249.554 -14.666
201806 -4.383 251.989 -5.744
201809 -4.647 252.439 -6.079
201812 -4.402 251.233 -5.786
201903 -7.933 254.202 -10.305
201906 -4.150 256.143 -5.350
201909 -5.059 256.759 -6.506
201912 -6.013 256.974 -7.727
202003 -7.060 258.115 -9.032
202006 -5.102 257.797 -6.535
202009 -9.245 260.280 -11.729
202012 -4.575 260.474 -5.800
202103 -8.813 264.877 -10.987
202106 2.543 271.696 3.091
202109 -6.782 274.310 -8.164
202112 -8.446 278.802 -10.003
202203 -9.014 287.504 -10.353
202206 -6.708 296.311 -7.475
202209 -7.946 296.808 -8.840
202212 -11.022 296.797 -12.263
202303 -8.658 301.836 -9.472
202306 -6.868 305.109 -7.433
202309 -4.136 307.789 -4.437
202312 -1.465 306.746 -1.577
202403 -11.815 312.332 -12.491
202406 -9.048 314.175 -9.510
202409 -5.923 315.301 -6.203
202412 -6.059 315.605 -6.339
202503 -11.500 319.799 -11.874
202506 -6.793 322.561 -6.954
202509 -5.134 324.800 -5.220
202512 -6.403 324.054 -6.525
202603 -11.222 330.213 -11.222

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of 円-40.69 mean?
MediciNova (TSE:4875) has a Cyclically Adjusted FCF per Share of 円-40.69 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on MediciNova and its competitors.
Is MediciNova's Cyclically Adjusted FCF per Share too high?
MediciNova's current Cyclically Adjusted FCF per Share is 円-40.69. Overall, MediciNova has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's Cyclically Adjusted FCF per Share compare to TCRX and PMVP?
MediciNova's Cyclically Adjusted FCF per Share of 円-40.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on MediciNova and its competitors. MediciNova's current Cyclically Adjusted FCF per Share is 円-40.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (TSE:4875) has a current Cyclically Adjusted FCF per Share of 円-40.69. The current Cyclically Adjusted FCF per Share is 円-40.69. MediciNova's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For MediciNova (TSE:4875), the current Cyclically Adjusted FCF per Share is 円-40.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediciNova Business Description

Other Exchanges MNOV:USA
Address 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
28GF Score

Get the complete analysis for TSE:4875

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円227.00
Price